The Effect of the Polyadenylation Inhibitor Cordycepin on MCF-7 Cells
Total Page:16
File Type:pdf, Size:1020Kb
Khurshid, Asma (2015) The effect of the polyadenylation inhibitor Cordycepin on MCF-7 cells. PhD thesis, University of Nottingham. Access from the University of Nottingham repository: http://eprints.nottingham.ac.uk/28835/1/PhD%20Thesis%20April%202015%20%28Examiner %20corrections%29.pdf Copyright and reuse: The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions. · Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. · To the extent reasonable and practicable the material made available in Nottingham ePrints has been checked for eligibility before being made available. · Copies of full items can be used for personal research or study, educational, or not- for-profit purposes without prior permission or charge provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. · Quotations or similar reproductions must be sufficiently acknowledged. Please see our full end user licence at: http://eprints.nottingham.ac.uk/end_user_agreement.pdf A note on versions: The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the repository url above for details on accessing the published version and note that access may require a subscription. For more information, please contact [email protected] The effect of the polyadenylation inhibitor Cordycepin on MCF-7 cells Asma Khurshid, MSc (University of Nottingham) Thesis submitted to the University of Nottingham for the degree of Doctor of Philosophy July 2015 Declaration Except where acknowledged in the text, I declare that this dissertation is my own work and is based on research that was undertaken by me in the School of Pharmacy, Faculty of Science, University of Nottingham. i Abstract Cordycepin (3-deoxyadenosine) is a medicinal bioactive component of the caterpillar fungi (Cordyceps and Ophicordyceps). It is reported to have nephroprotective, antiapoptotic, anti-metastatic, hepatoprotective (Yue et al. 2013), inflammatory effects, antioxidant, anti-tumor, immunomodulatory and vasorelaxation activities. Cordycepin is well known to terminate and inhibit polyadenylation, both in vitro and in vivo. Other proposed mechanisms of action of cordycepin include activation of adenosine receptors, activation of AMP dependent kinase (AMPK) and inhibition of PARP1. The purpose of this study is to elucidate the biological and pharmacological effects of cordycepin on cancer cell lines such as MCF-7 cells. In this study I found that cordycepin reduces the cell proliferation in all examined cell lines without always exerting an effect on 4EBP phosphorylation and protein synthesis rates. Therefore, the effects on protein synthesis via inhibition of mTOR, which were previously reported, are not only the sole reason for the effect of cordycepin on cell proliferation. Knockdown of poly (A) polymerases reduces cell proliferation and survival, indicating that poly (A) polymerases are potential targets of cordycepin. I studied different adenosine analogues and found that 8 aminoadenosine, the only one that also consistently inhibits polyadenylation, also reduces levels of P-4EBP. It also inhibits the expression of specific genes indicating that the effects on polyadenylation, mTOR signalling and gene expression are linked. Also consistent with polyadenylation inhibition as the major mode of action is the fact that the effects of cordycepin on gene expression are predominantly post-transcriptional. However, knockdown of poly (A) polymerases did not have the same effects on gene expression or on polyadenylation, indicating that cordycepin may act as a dominant negative rather than as a null mutant. This is consistent with the fact that cordycepin is known to arrest a normally transient polyadenylation complex. We performed microarray analysis of cordycepin treated MCF-7 cells and found that the downregulated mRNAs were predominantly involved in transcriptional regulation, cell proliferation, cell cycle and cell migration. These data show that ii cordycepin is a promising new drug for cancer and indicates that the mode of action it is likely to be through the inhibition of polyadenylation. iii Acknowledgements Firstly, I would like to thank to my supervisor Dr Cornelia H. de Moor for her great support, time, encouragement and co operation throughout my studies. It would not be possible for me to finish off my work without her understanding of my responsibilities being a mother and a student. I do not have enough words to convey my deepest thanks to her. I would also like to thank to Keith Spriggs for his advice and guidance during my studies and especially to Catherine Jopling for helping me to carry out my radiation work safely and efficiently in a friendly manner. I also liked to convey my deepest thanks to Anne Willis and her team (MRC Toxicology unit, Leicester) for her support in performing microarray analysis for this project. I would also like to thank to all of the past and present members of the RNA biology and gene regulation group, for their support and making my time enjoyable during the work particularly Hannah Parker, Hughes Alexandra and Andrew Lewis for their support, enjoyable chats and help during the work. Special thanks to Alexander Kondrashov for not only helping me in experimental work with great experience and expertise over the past three years but also for his conceptual guidance. I would like to thank to my family especially to my father for being supportive, encouraging and for having faith in my capabilities. I would always remain thankful to my late grandmother for her kindness, care and love which will always remain in my heart. Thanks to University of Nottingham for funding support. Lastly, love to my daughters Ayra and Arfa who always reminds me a cheerful and enjoyable face of life with her love, hug and endurable smiles which not only gives me strength but also boost up my energy after many sleepless nights especially during my final stages of research work. iv Table of content Declaration ........................................................................................................... i Abstract ............................................................................................................... ii Acknowledgements ............................................................................................. iv Table of content .................................................................................................. v List of Figures ...................................................................................................... xi List of Tables ...................................................................................................... xiii List of Abbreviations .......................................................................................... xiv 1 Introduction ................................................................................................. 1 1.1 Breast cancer ......................................................................................... 1 1.1.1 Molecular subtypes of breast cancer ..................................................... 1 1.1.2 Role of receptors in Breast cancer ......................................................... 2 1.1.2.1 HER2 ................................................................................................ 2 1.1.2.2 Hormone receptors......................................................................... 3 1.1.3 Breast cancer treatment ........................................................................ 3 1.1.3.1 HER2+ treatment ............................................................................. 4 1.1.3.2 Endocrine therapy .......................................................................... 4 1.1.3.3 Chemotherapy ................................................................................ 5 1.1.4 Molecular mechanisms of breast cancer ............................................... 7 1.1.5 Breast cancer hallmarks ......................................................................... 8 1.1.5.1 Sustaining proliferative signaling .................................................... 8 1.1.5.2 Evading growth suppressors ........................................................... 8 1.1.5.3 Capable of replicative immortality ................................................. 9 1.1.5.4 Activating invasion and metastasis ................................................. 9 1.1.5.5 Inducing angiogenesis ................................................................... 10 1.1.5.6 Resisting cell death ....................................................................... 10 1.1.6 Mutational analysis of human breast cancers: Role of tumour suppressor and oncogenes ................................................................................. 11 1.1.6.1 Breast cancer mutations ............................................................... 12 1.2 Signal transduction by the insulin and growth factor pathways in breast cancer 13 1.2.1 Role of tyrosine kinase receptors ........................................................ 13 1.2.1.1 EGFR signaling in breast cancer ...................................................